Edition:
India

Biocartis Group NV (BCART.BR)

BCART.BR on Brussels Stock Exchange

4.68EUR
6:00pm IST
Change (% chg)

€0.03 (+0.54%)
Prev Close
€4.66
Open
€4.70
Day's High
€4.71
Day's Low
€4.65
Volume
33,233
Avg. Vol
103,657
52-wk High
€6.88
52-wk Low
€2.75

Summary

Name Age Since Current Position

Christian Reinaudo

66 2018 Independent Chairman of the Board

Herman Verrelst

46 2017 Chief Executive Officer, Executive Director

Piet Houwen

52 2019 Chief Operating Officer

Benoit Devogelaere

39 2017 Chief Technology Officer

Roald Borre

47 2016 Non-Executive Director

Luc Gijsens

67 2018 Non-Executive Independent Director

Harry Glorikian

54 2018 Non-Executive Independent Director

Leo Steenbergen

67 2018 Non-Executive Independent Director

Ann-Christine Sundell

56 2018 Non-Executive Independent Director

Renate Degrave

Head of Investor Relations & Corporate Communications

Biographies

Name Description

Christian Reinaudo

Dr. Christian Reinaudo serves as Independent Chairman of the Board of the Company. He is permanently representing CRBA Management BVBA. Mr. Reinaudo joined Agfa-Gevaert, a health & digital imaging solutions provider, as president of the Agfa HealthCare business group and member of the executive committee, on January 1, 2008. Mr. Reinaudo started his career with Alcatel in 1978 at the research center at Marcoussis, France. In 1984, he joined Alcatel's cable activities where he became responsible for research associated with fiber optics and cable for undersea applications. In 1997, he became president of Alcatel's Submarine Networks Division. From 1999 to 2003, he was president of the Alcatel Optics Group, which comprises all activities in terrestrial and submarine transmission networking and optoelectronic components. In 2003, he was appointed president of Alcatel Asia Pacific and moved to Shanghai (China), where he stayed until 2006, also serving as vice chairman of the board of directors of Alcatel Shanghai Bell, the Chinese joint venture between Alcatel and the Chinese government. In his latest position at Alcatel, he was president Europe & North for Alcatel-Lucent and was responsible for the integration and transition process during the merger of Alcatel with Lucent Technologies. In 2010, Mr. Reinaudo was appointed CEO of Agfa-Gevaert and became a member of the board. Mr. Reinaudo is also member of the supervisory board of Domo Chemicals GmbH since 2016.

Herman Verrelst

Mr. Herman Verrelst serves as Chief Executive Officer, Executive Director of the Company. He is a seasoned executive and serial entrepreneur with a proven international commercial track-record in molecular diagnostics. Prior to joining Biocartis, Herman Verrelst held the position of vice president and general manager of the genomics and clinical applications division of Agilent Technologies. Mr. Verrelst joined Agilent following Agilent's acquisition of Cartagenia, a spin-off of Katholieke Universiteit Leuven (Belgium) focused on software solutions for clinical genetics and molecular oncology, of which Herman Verrelst was CEO and founder. Prior to that, Herman Verrelst was CEO of Medicim as well as founder and CEO of DATA4s. He also has board mandates at South Bay Ventures (SBV) BVBA, Opdorp Finance BVBA, Icometrix and FlandersBio VZW, Fox Biosystems NV.

Piet Houwen

Mr. Piet Houwen serves as Chief Operating Officer of the Company. With more than 25 years in various operational and general management roles, Piet Houwen has a strong track record in manufacturing, process engineering, project and people management. Piet Houwen has gained broad operational experience in dynamic international environments, including in fast moving consumer goods, food manufacturing, bio-pharmaceuticals and consulting. Prior to joining Biocartis, Piet Houwen was Chief Operations Officer at Ablynx and prior to that, he held global roles for Sanofi/Genzyme and Janssen Pharmaceutica (part of Johnson & Johnson family of companies) where he was active in pharmaceutical manufacturing of large and small molecules, stent coating and medical devices. Piet Houwen holds a Master’s Degree in Mechanical Engineering from the Delft University of Technology (The Netherlands).

Benoit Devogelaere

Mr. Benoit Devogelaere serves as Chief Technology Officer of the Company. He started his career in the pharmaceutical sector (Johnson and Johnson) in virology. In 2011, he joined Biocartis to lead the first CE-IVD marking of an Idylla test. In 2013, he joined Cartagenia, a provider of diagnostic software, as R&D Operating Manager to further expand the Cartagenia product portfolio. In 2015, following the acquisition of Cartagenia by Agilent Technologies (NYSE: A), Mr. Devogelaere relocated to Silicon Valley, US where he was responsible for several aspects of the portfolio strategy, product roadmapping and technology scouting. End of 2017, Mr. Devogelaere join Biocartis as chief technology officer. He holds a Master in biological engineering and a PhD in medical sciences (University of Leuven, Belgium).

Roald Borre

Mr. Roald Borre serves as Non-Executive Director of the Company. He started his professional career at the Financieel Economische Tijd newspaper as a financial analyst specialized in high-tech companies, particularly in the ICT and biotech fields. He was responsible for the launch of Wall Street Invest, a weekly with a focus on Nasdaq-listed (mainly) biotech and ICT companies. In 1999, he joined Puilaetco Private Bankers as senior fund manager, where he was in charge of the Biotechnology Fund and managed various investments in the therapeutics and diagnostics field, a position he held until 2006. In 2011, after five years as an entrepreneur, Mr. Borre joined the ParticipatieMaatschappij Vlaanderen as business and fund manager of the TINA fund that focused on industrial projects with a high degree of innovation and the potential to transform, also adding head of equity investments to his responsibilities. He is on the board of different PMV portfolio companies and a member of several advisory boards. Mr. Borre holds a Masters in financial and commercial sciences (specialization accountancy) from EHSAL Management School, Belgium. He holds mandates at High Wind NV, FNG Group NV, miDiagnostics NV, Capricorn Cleantech Fund NV, Laboratoria Smeets NV, Newtech Group NV and Newtec Cy NV, Innovation Fund NV, Kebony AS, Media Invest Vlaanderen NV, Comics Station NV.

Luc Gijsens

Mr. Luc Gijsens serves as Non-Executive Independent Director of the Company. He is permanently representing Luc Gijsens BVBA. He is a highly experienced international executive with deep knowledge in a wide range of areas in finance and capital markets, asset management, corporate and investment banking in Belgium and abroad. He served KBC Group, a leading bank & insurance group in Belgium and Central Europe for 40 years in a wide range of responsibilities. Mr. Gijsens retired from KBC Group in 2017 as CEO of the business unit International Markets and executive director of KBC Bank & Insurance, responsible for the market activities of KBC Group. He acted as chairman of the board of KBC Securities and KBC Asset Management and as chairman of the board of the banking and insurance subsidiaries in Ireland, the Slovak Republic, Hungary and Bulgaria. Prior to that, Mr. Gijsens served as senior general manager of KBC Bank, responsible for corporate banking in Belgium, Western Europe, Asia Pacific and the US. He also holds board mandates at Luc Gijsens BVBA, Arvesta NV and PMV NV.

Harry Glorikian

Mr. Harry A. Glorikian serves as Non-Executive Independent Director of the Company. He is permanently representing Scientia II LLC. is an influential global business expert with more than three decades of experience building ventures in North America, Europe, Asia and the rest of the world. He is well known for achievements in life sciences, healthcare, diagnostics, healthcare IT and the convergence of these areas. Mr. Glorikian currently serves as general partner at New Ventures Funds. Prior to that, he served as an ‘Entrepreneur In Residence' to GE Ventures – New Business Creation Group. He currently serves on the board of GeneNews Ltd. and serves on the advisory board of Evidation Health and several other companies. He is also a co- founder and advisory board member of DrawBridge Health. Previously he co-founded and held the position of managing director and head of consulting services for Scientia Advisors, which was acquired by Precision for Medicine in November 2012. Among his other professional roles, Mr. Glorikian served as senior manager for global business development at PE Applied Biosystems, founded X-Cell Laboratories, managed global sales at Signet Laboratories and held various roles at BioGenex Laboratories. Mr. Glorikian holds a Masters of Business Administration from the Boston University and a BA in General Biology from San Francisco State University.

Leo Steenbergen

Mr. Leo Steenbergen serves as Non-Executive Independent Director of the Company. He is permanently representing CLSCO BVBA. He has a longstanding international experience having served both privately held and listed companies as CFO or general manager, including at Galapagos, Telenet and the Bekaert Group. He is director and member of the audit committee of the private equity held Metallum Holdings in The Netherlands, a leading European recycling and refining company of non-ferro metal scrap with operations in Belgium and Spain. Prior to that, Mr. Steenbergen was active in a variety of senior international finance and administration roles at Hewlett Packard Europe and served as director in several companies based in Europe, the US, Canada, Australia and Hong Kong. He also holds board mandates at CLSCO BVBA, Metallum Holdings BV and LEDSky BVBA, Antwerp Metals NV.

Ann-Christine Sundell

Mrs. Ann-Christine Sundell serves as Non-Executive Independent Director of the Company. She has more than 30 years of experience in the diagnostics and life science sector, where she held various global senior positions. For 10 years she served as president for the Genetic Screening (diagnostics) strategic business unit within PerkinElmer, one of the world’s leading life science companies. Mrs. Sundell has deep strategic and operational experience from building, developing and managing global growth businesses. She currently serves as chairman of the board of Oy Medix Biochemica group Ab and Serres Oy and is a board member of Blueprint Genetics Oy, Immunovia Ab, Ledil Group Oy, Ledil Oy, Raisio Oyj, Revenio Group Oyj, Committee Member of Raisio Oyj’s Research Foundation, member of the nomination and remuneration committee of Raisio Oyj and holder of AConsult. Mrs. Sundell holds an MSc in biochemistry from Abo Akademi, Turku, Finland.

Renate Degrave

Basic Compensation